| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Blood Platelets | 10 | 2019 | 1704 | 1.23 | Why? |
| Hemorrhage | 14 | 2018 | 3013 | 1.20 | Why? |
| Blood Coagulation | 17 | 2020 | 2768 | 1.16 | Why? |
| Anticoagulants | 16 | 2021 | 9563 | 1.05 | Why? |
| Peripheral Arterial Disease | 6 | 2020 | 471 | 0.90 | Why? |
| Heparin, Low-Molecular-Weight | 3 | 2021 | 1731 | 0.84 | Why? |
| Thrombin | 8 | 2018 | 325 | 0.83 | Why? |
| Blood Coagulation Tests | 6 | 2021 | 855 | 0.78 | Why? |
| Blood Coagulation Factors | 3 | 2017 | 223 | 0.76 | Why? |
| Factor VIIa | 1 | 2018 | 27 | 0.75 | Why? |
| Platelet Aggregation Inhibitors | 4 | 2018 | 1671 | 0.72 | Why? |
| Factor X Deficiency | 1 | 2017 | 17 | 0.70 | Why? |
| Rivaroxaban | 2 | 2018 | 467 | 0.68 | Why? |
| Factor Xa Inhibitors | 3 | 2018 | 490 | 0.66 | Why? |
| Platelet Activation | 5 | 2018 | 660 | 0.65 | Why? |
| Factor Xa | 1 | 2017 | 113 | 0.65 | Why? |
| Thrombosis | 12 | 2021 | 7504 | 0.60 | Why? |
| Drug Monitoring | 3 | 2018 | 1408 | 0.59 | Why? |
| Postthrombotic Syndrome | 3 | 2018 | 15 | 0.56 | Why? |
| Decision Support Techniques | 4 | 2018 | 903 | 0.55 | Why? |
| Thrombocytopenia | 4 | 2018 | 2093 | 0.49 | Why? |
| Drug Information Services | 1 | 2012 | 26 | 0.48 | Why? |
| Fibrinolytic Agents | 3 | 2020 | 1702 | 0.47 | Why? |
| Hematology | 1 | 2018 | 649 | 0.46 | Why? |
| Purinergic P2Y Receptor Antagonists | 1 | 2012 | 206 | 0.40 | Why? |
| Pulmonary Embolism | 6 | 2020 | 4775 | 0.39 | Why? |
| Peptide Hydrolases | 1 | 2017 | 1269 | 0.39 | Why? |
| Netherlands | 9 | 2020 | 3533 | 0.38 | Why? |
| Stockings, Compression | 2 | 2018 | 20 | 0.38 | Why? |
| Venous Thromboembolism | 5 | 2020 | 4273 | 0.37 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.36 | Why? |
| Endothelium, Vascular | 2 | 2018 | 1751 | 0.35 | Why? |
| Hemostasis | 5 | 2018 | 811 | 0.34 | Why? |
| Platelet Function Tests | 5 | 2018 | 231 | 0.32 | Why? |
| Thromboembolism | 5 | 2020 | 2101 | 0.31 | Why? |
| Long-Term Care | 1 | 2017 | 2047 | 0.29 | Why? |
| Dabigatran | 2 | 2017 | 204 | 0.29 | Why? |
| Hematologic Neoplasms | 1 | 2018 | 2105 | 0.29 | Why? |
| Fibrin Fibrinogen Degradation Products | 7 | 2020 | 5993 | 0.29 | Why? |
| Thromboplastin | 2 | 2018 | 275 | 0.29 | Why? |
| Administration, Oral | 5 | 2018 | 2340 | 0.28 | Why? |
| Vascular Stiffness | 2 | 2018 | 264 | 0.27 | Why? |
| Cardiovascular Diseases | 7 | 2018 | 11497 | 0.27 | Why? |
| Thrombophilia | 3 | 2021 | 1935 | 0.26 | Why? |
| Cardiology | 1 | 2018 | 2873 | 0.26 | Why? |
| Diabetes Mellitus, Experimental | 1 | 2005 | 192 | 0.25 | Why? |
| Collagen | 3 | 2019 | 222 | 0.25 | Why? |
| Coronary Artery Disease | 1 | 2018 | 2570 | 0.25 | Why? |
| Renal Insufficiency, Chronic | 1 | 2017 | 2654 | 0.24 | Why? |
| Consensus | 1 | 2017 | 6345 | 0.24 | Why? |
| Acute Coronary Syndrome | 2 | 2017 | 2107 | 0.24 | Why? |
| Non-ST Elevated Myocardial Infarction | 2 | 2018 | 490 | 0.24 | Why? |
| Receptors, Thrombin | 2 | 2018 | 22 | 0.23 | Why? |
| Computed Tomography Angiography | 4 | 2020 | 2153 | 0.23 | Why? |
| Glomerular Filtration Rate | 2 | 2019 | 1262 | 0.23 | Why? |
| Cancer Survivors | 2 | 2018 | 588 | 0.22 | Why? |
| Cost-Benefit Analysis | 3 | 2018 | 2259 | 0.21 | Why? |
| Platelet Aggregation | 6 | 2019 | 318 | 0.21 | Why? |
| Venous Thrombosis | 5 | 2019 | 2739 | 0.21 | Why? |
| Platelet Membrane Glycoproteins | 1 | 2019 | 42 | 0.20 | Why? |
| Syk Kinase | 1 | 2019 | 32 | 0.20 | Why? |
| Atrial Fibrillation | 4 | 2018 | 2320 | 0.20 | Why? |
| Phenprocoumon | 1 | 2018 | 3 | 0.20 | Why? |
| Superior Vena Cava Syndrome | 1 | 2019 | 26 | 0.19 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.19 | Why? |
| Receptor, PAR-1 | 1 | 2018 | 24 | 0.19 | Why? |
| Random Allocation | 2 | 2018 | 773 | 0.19 | Why? |
| Intermittent Claudication | 1 | 2018 | 26 | 0.19 | Why? |
| Mean Platelet Volume | 2 | 2018 | 203 | 0.18 | Why? |
| Iliac Artery | 1 | 2018 | 50 | 0.18 | Why? |
| Vascular Remodeling | 1 | 2018 | 99 | 0.18 | Why? |
| Vitamin K | 2 | 2017 | 263 | 0.18 | Why? |
| Blood Platelet Disorders | 1 | 2017 | 44 | 0.17 | Why? |
| Poisson Distribution | 1 | 2018 | 348 | 0.17 | Why? |
| Risk Assessment | 10 | 2020 | 25439 | 0.17 | Why? |
| Platelet-Rich Plasma | 1 | 2018 | 91 | 0.17 | Why? |
| Platelet Transfusion | 1 | 2018 | 209 | 0.17 | Why? |
| Cerebral Infarction | 1 | 2020 | 245 | 0.17 | Why? |
| Multiple Trauma | 1 | 2017 | 80 | 0.16 | Why? |
| Angina, Unstable | 1 | 2017 | 110 | 0.16 | Why? |
| Risk Factors | 18 | 2020 | 71621 | 0.16 | Why? |
| Fibrinogen | 3 | 2018 | 1048 | 0.16 | Why? |
| Blood Loss, Surgical | 1 | 2018 | 211 | 0.16 | Why? |
| Prothrombin | 1 | 2017 | 149 | 0.16 | Why? |
| Postoperative Hemorrhage | 1 | 2018 | 183 | 0.16 | Why? |
| Thrombelastography | 2 | 2021 | 627 | 0.16 | Why? |
| Athletic Performance | 1 | 2018 | 208 | 0.15 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.15 | Why? |
| Lipoproteins | 1 | 2017 | 240 | 0.15 | Why? |
| Reperfusion Injury | 1 | 2017 | 178 | 0.15 | Why? |
| Humans | 62 | 2021 | 930598 | 0.15 | Why? |
| Carotid Stenosis | 1 | 2018 | 207 | 0.14 | Why? |
| Aged | 33 | 2020 | 215776 | 0.14 | Why? |
| Disseminated Intravascular Coagulation | 2 | 2020 | 994 | 0.14 | Why? |
| Middle Aged | 36 | 2020 | 270681 | 0.14 | Why? |
| Dose-Response Relationship, Drug | 2 | 2021 | 3776 | 0.14 | Why? |
| Clinical Laboratory Techniques | 2 | 2018 | 23402 | 0.14 | Why? |
| Complement Activation | 1 | 2020 | 949 | 0.13 | Why? |
| Automation, Laboratory | 1 | 2017 | 536 | 0.13 | Why? |
| Clinical Decision-Making | 2 | 2018 | 3755 | 0.13 | Why? |
| Plaque, Atherosclerotic | 1 | 2018 | 423 | 0.13 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.13 | Why? |
| Male | 42 | 2020 | 367725 | 0.13 | Why? |
| Proteolysis | 1 | 2017 | 751 | 0.13 | Why? |
| Factor VIII | 1 | 2015 | 229 | 0.12 | Why? |
| Female | 40 | 2020 | 380317 | 0.12 | Why? |
| Kidney | 2 | 2017 | 3648 | 0.12 | Why? |
| Fibrosis | 3 | 2018 | 800 | 0.12 | Why? |
| Predictive Value of Tests | 5 | 2018 | 9537 | 0.12 | Why? |
| von Willebrand Factor | 1 | 2018 | 668 | 0.12 | Why? |
| Renal Insufficiency | 1 | 2019 | 810 | 0.11 | Why? |
| Thiophenes | 1 | 2012 | 78 | 0.11 | Why? |
| Extracellular Traps | 1 | 2020 | 1036 | 0.11 | Why? |
| Reproducibility of Results | 7 | 2018 | 11304 | 0.11 | Why? |
| Prasugrel Hydrochloride | 1 | 2012 | 114 | 0.11 | Why? |
| Mitochondria | 1 | 2018 | 857 | 0.11 | Why? |
| Antithrombins | 3 | 2017 | 353 | 0.11 | Why? |
| Ticlopidine | 1 | 2012 | 193 | 0.10 | Why? |
| Patient Selection | 2 | 2018 | 4560 | 0.10 | Why? |
| Hematologic Diseases | 1 | 2017 | 614 | 0.10 | Why? |
| Athletes | 1 | 2018 | 1047 | 0.10 | Why? |
| Drugs, Generic | 1 | 2012 | 136 | 0.10 | Why? |
| Pulmonary Artery | 1 | 2017 | 803 | 0.10 | Why? |
| Israel | 1 | 2018 | 2751 | 0.10 | Why? |
| Neoplasms | 4 | 2019 | 17251 | 0.10 | Why? |
| Inflammation Mediators | 2 | 2018 | 2654 | 0.10 | Why? |
| Anemia | 1 | 2017 | 789 | 0.10 | Why? |
| Aged, 80 and over | 11 | 2020 | 88759 | 0.10 | Why? |
| DNA | 1 | 2015 | 778 | 0.10 | Why? |
| Polymorphism, Genetic | 2 | 2015 | 1074 | 0.09 | Why? |
| Quality of Life | 3 | 2019 | 9820 | 0.09 | Why? |
| Endovascular Procedures | 1 | 2019 | 1302 | 0.09 | Why? |
| Inflammation | 4 | 2018 | 13255 | 0.09 | Why? |
| Piperazines | 1 | 2012 | 445 | 0.09 | Why? |
| Blood Transfusion | 1 | 2018 | 1399 | 0.09 | Why? |
| Treatment Outcome | 6 | 2019 | 51732 | 0.09 | Why? |
| Stroke Volume | 1 | 2018 | 2153 | 0.09 | Why? |
| Arteriosclerosis | 2 | 2004 | 50 | 0.09 | Why? |
| Drug Costs | 1 | 2012 | 313 | 0.09 | Why? |
| Adenosine | 1 | 2012 | 509 | 0.09 | Why? |
| Time Factors | 7 | 2018 | 31397 | 0.09 | Why? |
| Point-of-Care Testing | 2 | 2017 | 2782 | 0.08 | Why? |
| Prognosis | 6 | 2020 | 32490 | 0.08 | Why? |
| Adult | 20 | 2020 | 244371 | 0.08 | Why? |
| Biomarkers | 11 | 2018 | 23361 | 0.08 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2017 | 9335 | 0.07 | Why? |
| Renal Circulation | 1 | 2005 | 44 | 0.07 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.07 | Why? |
| Health Care Costs | 1 | 2014 | 1007 | 0.07 | Why? |
| Flow Cytometry | 3 | 2018 | 2393 | 0.07 | Why? |
| Germany | 5 | 2018 | 9196 | 0.07 | Why? |
| Monocytes | 1 | 2017 | 2978 | 0.07 | Why? |
| Cardiac Surgical Procedures | 1 | 2018 | 1931 | 0.07 | Why? |
| Staining and Labeling | 1 | 2005 | 169 | 0.07 | Why? |
| Decision Making | 1 | 2018 | 3132 | 0.07 | Why? |
| Fibrin | 1 | 2005 | 145 | 0.07 | Why? |
| Reference Standards | 2 | 2018 | 1163 | 0.07 | Why? |
| Kidney Glomerulus | 1 | 2005 | 144 | 0.07 | Why? |
| Neutrophils | 1 | 2020 | 5476 | 0.07 | Why? |
| Kidney Tubules | 1 | 2005 | 205 | 0.06 | Why? |
| Homocysteine | 1 | 2004 | 83 | 0.06 | Why? |
| Mice | 2 | 2018 | 21357 | 0.06 | Why? |
| Disease Models, Animal | 3 | 2017 | 10998 | 0.06 | Why? |
| Surveys and Questionnaires | 3 | 2019 | 43792 | 0.06 | Why? |
| Myocardial Infarction | 1 | 2018 | 3361 | 0.06 | Why? |
| Prospective Studies | 8 | 2019 | 43301 | 0.06 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.06 | Why? |
| Cohort Studies | 4 | 2020 | 36005 | 0.06 | Why? |
| Proportional Hazards Models | 3 | 2020 | 6543 | 0.06 | Why? |
| Incidence | 6 | 2020 | 25622 | 0.06 | Why? |
| Platelet Count | 2 | 2018 | 1381 | 0.06 | Why? |
| Animals | 7 | 2018 | 78931 | 0.06 | Why? |
| Nadroparin | 1 | 2020 | 9 | 0.05 | Why? |
| ST Elevation Myocardial Infarction | 1 | 2017 | 3051 | 0.05 | Why? |
| Follow-Up Studies | 5 | 2018 | 17020 | 0.05 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.05 | Why? |
| Glucose | 1 | 2005 | 573 | 0.05 | Why? |
| Immunohistochemistry | 2 | 2005 | 2275 | 0.05 | Why? |
| Reference Values | 2 | 2017 | 795 | 0.05 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.05 | Why? |
| Stroke | 3 | 2018 | 8839 | 0.05 | Why? |
| Cyclohexylamines | 1 | 2019 | 35 | 0.05 | Why? |
| Genetic Predisposition to Disease | 1 | 2015 | 4027 | 0.05 | Why? |
| Regression Analysis | 2 | 2018 | 2484 | 0.05 | Why? |
| Protein C | 1 | 2000 | 141 | 0.05 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.05 | Why? |
| C-Reactive Protein | 4 | 2018 | 7972 | 0.05 | Why? |
| Elastin | 1 | 2018 | 16 | 0.05 | Why? |
| Factor X | 1 | 2018 | 18 | 0.05 | Why? |
| Ankle Brachial Index | 1 | 2018 | 53 | 0.05 | Why? |
| Frontal Lobe | 1 | 2020 | 191 | 0.05 | Why? |
| Myofibroblasts | 1 | 2018 | 61 | 0.05 | Why? |
| Case-Control Studies | 4 | 2018 | 17671 | 0.05 | Why? |
| Atrial Natriuretic Factor | 1 | 2018 | 75 | 0.05 | Why? |
| Evidence-Based Medicine | 1 | 2012 | 3228 | 0.05 | Why? |
| CX3C Chemokine Receptor 1 | 1 | 2017 | 21 | 0.05 | Why? |
| Rupture, Spontaneous | 1 | 2018 | 115 | 0.05 | Why? |
| Registries | 1 | 2018 | 12327 | 0.04 | Why? |
| CD11b Antigen | 1 | 2017 | 90 | 0.04 | Why? |
| Peptide Fragments | 2 | 2019 | 2075 | 0.04 | Why? |
| Population Surveillance | 1 | 2015 | 4967 | 0.04 | Why? |
| Constriction, Pathologic | 1 | 2018 | 212 | 0.04 | Why? |
| Carotid Intima-Media Thickness | 1 | 2018 | 179 | 0.04 | Why? |
| Calcium Signaling | 1 | 2018 | 133 | 0.04 | Why? |
| Antidotes | 1 | 2017 | 46 | 0.04 | Why? |
| Elasticity | 1 | 2017 | 70 | 0.04 | Why? |
| Adenosine Diphosphate | 1 | 2017 | 63 | 0.04 | Why? |
| Apoptosis | 2 | 2018 | 2335 | 0.04 | Why? |
| Italy | 2 | 2018 | 38444 | 0.04 | Why? |
| Hematocrit | 1 | 2017 | 107 | 0.04 | Why? |
| Arachidonic Acid | 1 | 2017 | 90 | 0.04 | Why? |
| Magnetic Resonance Angiography | 1 | 2018 | 282 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.04 | Why? |
| Algorithms | 3 | 2019 | 7346 | 0.04 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.04 | Why? |
| Heart Failure | 1 | 2018 | 6638 | 0.04 | Why? |
| Sex Factors | 3 | 2020 | 11014 | 0.04 | Why? |
| Sus scrofa | 1 | 2017 | 205 | 0.04 | Why? |
| Adrenomedullin | 1 | 2018 | 217 | 0.04 | Why? |
| Conservative Treatment | 1 | 2019 | 349 | 0.04 | Why? |
| Necrosis | 1 | 2018 | 532 | 0.04 | Why? |
| Adolescent | 4 | 2018 | 86841 | 0.04 | Why? |
| International Normalized Ratio | 1 | 2017 | 300 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.04 | Why? |
| Megakaryocytes | 1 | 2017 | 274 | 0.04 | Why? |
| Probability | 1 | 2019 | 923 | 0.04 | Why? |
| Health Status Indicators | 1 | 2018 | 341 | 0.03 | Why? |
| Protein Precursors | 1 | 2018 | 425 | 0.03 | Why? |
| Retrospective Studies | 4 | 2020 | 105322 | 0.03 | Why? |
| Cadaver | 1 | 2018 | 626 | 0.03 | Why? |
| Mice, Inbred C57BL | 1 | 2005 | 5542 | 0.03 | Why? |
| Young Adult | 4 | 2018 | 93724 | 0.03 | Why? |
| Cellular Senescence | 1 | 2017 | 326 | 0.03 | Why? |
| Warfarin | 1 | 2018 | 402 | 0.03 | Why? |
| Vascular Calcification | 1 | 2018 | 396 | 0.03 | Why? |
| Survival Rate | 2 | 2018 | 9206 | 0.03 | Why? |
| Tissue Plasminogen Activator | 1 | 2020 | 778 | 0.03 | Why? |
| False Positive Reactions | 1 | 2019 | 1338 | 0.03 | Why? |
| Single-Blind Method | 1 | 2017 | 1283 | 0.03 | Why? |
| Echocardiography, Transesophageal | 1 | 2017 | 447 | 0.03 | Why? |
| Epithelial Cells | 1 | 2005 | 3508 | 0.03 | Why? |
| Immunophenotyping | 1 | 2017 | 1290 | 0.03 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.03 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| Stents | 1 | 2019 | 916 | 0.03 | Why? |
| Natriuretic Peptide, Brain | 1 | 2018 | 1215 | 0.03 | Why? |
| Pyrimidines | 1 | 2019 | 1557 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.03 | Why? |
| Pain | 1 | 2019 | 1084 | 0.03 | Why? |
| Quality-Adjusted Life Years | 1 | 2014 | 511 | 0.03 | Why? |
| Up-Regulation | 1 | 2018 | 2249 | 0.03 | Why? |
| Homes for the Aged | 1 | 2020 | 1071 | 0.03 | Why? |
| Recurrence | 1 | 2020 | 3675 | 0.03 | Why? |
| Propensity Score | 1 | 2018 | 2690 | 0.02 | Why? |
| Safety | 1 | 2017 | 1583 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2020 | 3786 | 0.02 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.02 | Why? |
| Protein Kinase Inhibitors | 1 | 2019 | 1585 | 0.02 | Why? |
| Swine | 1 | 2017 | 3352 | 0.02 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Cells, Cultured | 1 | 2019 | 5835 | 0.02 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1573 | 0.02 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.02 | Why? |
| Sex Distribution | 1 | 2015 | 2083 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2019 | 22971 | 0.02 | Why? |
| Age Factors | 2 | 2018 | 21039 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2018 | 3444 | 0.02 | Why? |
| Telemedicine | 1 | 2017 | 25032 | 0.02 | Why? |
| Age Distribution | 1 | 2015 | 3567 | 0.02 | Why? |
| Survival Analysis | 1 | 2019 | 7592 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2004 | 37 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Bias | 1 | 2009 | 1109 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.02 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2004 | 6166 | 0.02 | Why? |
| Nursing Homes | 1 | 2020 | 4155 | 0.02 | Why? |
| Genotype | 1 | 2015 | 4697 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.02 | Why? |
| Electrocardiography | 1 | 2017 | 3957 | 0.02 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.02 | Why? |
| Liver | 1 | 2017 | 4007 | 0.01 | Why? |
| Patient Safety | 1 | 2017 | 4885 | 0.01 | Why? |
| Cell Nucleus | 1 | 2004 | 399 | 0.01 | Why? |
| Specimen Handling | 1 | 2018 | 6190 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.01 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.01 | Why? |
| Kidney Transplantation | 1 | 2017 | 5397 | 0.01 | Why? |
| NF-kappa B | 1 | 2004 | 1301 | 0.01 | Why? |
| Seasons | 1 | 2009 | 4071 | 0.01 | Why? |
| Endotoxemia | 1 | 1997 | 143 | 0.01 | Why? |
| Cytokines | 1 | 1997 | 15010 | 0.01 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.01 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Pandemics | 4 | 2020 | 389249 | 0.01 | Why? |
| Fibrinolysis | 1 | 1997 | 521 | 0.01 | Why? |
| Lung | 1 | 2020 | 31049 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Child | 1 | 2018 | 70012 | 0.01 | Why? |
| Bacteremia | 1 | 1997 | 1372 | 0.00 | Why? |
| Blood Coagulation Disorders | 1 | 1997 | 2040 | 0.00 | Why? |
| Sepsis | 1 | 1997 | 3517 | 0.00 | Why? |